Key Points
Pharma as a sector has been under pressure for a very long time..
However, some of the small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies have been facing keep attracting interest from the analyst..
The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list...
Select domestic pharma companies which have been pushing for backward integration have seen some improvement in their margins..
At the same time some headwinds have again resurfaced for large pharma companies whose fortunes are tied up with pricing trends in US markets..
You might be interested in
On a path to recovery: 4 small pharma stocks with an upside potential of up to 27%
14, May, 23As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.
New tailwinds emerge! 5 midcap pharma stocks with upside potential of up to 37%
05, Nov, 23If one looks at corporate announcements, a large number of small and mid-caps pharma companies are announcing one or the other thing either about US FDA or European authorities giving approval or inspection. While the large players had moved to international markets a long time back, a number of small companies that had domestic focussed business are also moving into the developed global markets. Will this lead to re-rating?
Finally out of the woods? 4 small and midcap pharma stocks with an upside potential of up to 26%
28, Jun, 23Pharma as a sector has been under pressure for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets have been troubling the sector. However, some of the small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies have been facing keep attracting interest from the analyst. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.